We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell t... Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. Show more
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...
-Enrollment Complete in Cohort A of Phase 3, Pivotal, HOPE-3 Trial of CAP-1002 inΒ Duchenne Muscular Dystrophy; Announced Successful Interim Futility Analysis; On Track to Report Top-Line Data in...
SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- β Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and...
-Cohort B of HOPE-3, Phase 3 Clinical Trial Expected to Complete Enrollment in Second Quarter 2024- SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.15 | -18.3121019108 | 6.28 | 6.47 | 4.685 | 328081 | 5.90395092 | CS |
4 | -1.79 | -25.8670520231 | 6.92 | 7.28 | 4.685 | 318983 | 6.44779145 | CS |
12 | 1.04 | 25.4278728606 | 4.09 | 7.28 | 3.56 | 275192 | 5.65979174 | CS |
26 | 2.32 | 82.5622775801 | 2.81 | 7.28 | 2.68 | 259332 | 4.74175246 | CS |
52 | 0.84 | 19.5804195804 | 4.29 | 8.2212 | 2.68 | 206424 | 4.71832812 | CS |
156 | 1.1 | 27.2952853598 | 4.03 | 8.2212 | 2.56 | 265197 | 4.55705495 | CS |
260 | 4.62 | 905.882352941 | 0.51 | 12.32 | 0.2526 | 761193 | 5.883649 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions